BOSTON--(BUSINESS WIRE)--
Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) and peripheral neuropathies such as Charcot-Marie-Tooth (CMT), today announced that it will present at the BIO CEO conference in New York, NY on February 13, 2018.
A live webcast of Flex Pharma’s presentations at these conferences may be accessed in the Investor section of the Company’s website at www.flex-pharma.com. Please log on to the Flex Pharma website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Flex Pharma’s website for 2 weeks following each presentation.
About Flex Pharma
Flex Pharma, Inc. is a clinical-stage
biotechnology company that is developing innovative and proprietary
treatments in Phase 2 randomized, controlled trials for cramps and
spasticity associated with the severe neurological diseases of ALS, MS
and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). The
Company’s lead candidate, FLX-787, is being developed under Fast Track
designation for the treatment of severe muscle cramps associated with
ALS. Flex Pharma was founded by National Academy of Science members Rod
MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized
leaders in the fields of ion channels and neurobiology, along with
Christoph Westphal, M.D., Ph.D.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180206005987/en/
